CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
胶质瘤的疫苗免疫治疗及相关临床前模型
英文原题：Vaccine-based immunotherapy and related preclinical models for glioma.
查看英文原题
Vaccine-based immunotherapy and related preclinical models for glioma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胶质瘤是最常见的中枢神经系统原发恶性肿瘤，缺乏有效治疗；其中超过60%为侵袭性最强的胶质母细胞瘤。尽管免疫疗法有所进步，胶质母细胞瘤仍高度耐受。靶向肿瘤抗原推动了多种免疫疗法发展，包括个体化肿瘤疫苗、患者特异性靶点选择、树突状细胞疫苗以及CAR-T 和TCR-T。近期研究在胶质母细胞瘤和低级别胶质瘤中显示希望。本文综述胶质瘤疫苗、免疫学研究临床前模型及CD4阳性T细胞在疫苗诱导抗肿瘤免疫中的作用，并总结临床策略、挑战和开发更有效疫苗的未来研究方向。
展开英文摘要原文
Glioma, the most common primary malignant tumor in the central nervous system (CNS), lacks effective treatments, and >60% of cases are glioblastoma (GBM), the most aggressive form. Despite advances in immunotherapy, GBM remains highly resistant. Approaches that target tumor antigens expedite the development of immunotherapies, including personalized tumor-specific vaccines, patient-specific target selection, dendritic cell (DC) vaccines, and chimeric antigen receptor (CAR) and T cell receptor (TCR) T cells.
Recent studies show promising results in treating GBM and lower-grade glioma (LGG), fostering hope for future immunotherapy. This review discusses tumor vaccines against glioma, preclinical models in immunological research, and the role of CD4 + T cells in vaccine-induced antitumor immunity.
We also summarize clinical approaches, challenges, and future research for creating more effective vaccines.
论文信息
- 作者
- Yao L、Hatami M、Ma W、Skutella T
- 第一作者单位
- Institute for Anatomy and Cell Biology, Heidelberg Medical Faculty, Heidelberg University, Heidelberg, Germany.Germany
- 通讯作者单位
- Institute for Anatomy and Cell Biology, Heidelberg Medical Faculty, Heidelberg University, Heidelberg, Germany. Electronic address: thomas.skutella@uni-heidelberg.de.Germany
- 文献类型
- 综述
- 期刊
- Trends in molecular medicine2024 Oct
- 原文标识
- PubMed 39013724 · DOI 10.1016/j.molmed.2024.06.009